Navigation Links
Schering-Plough Reports Financial Results for Third Quarter of 2008
Date:10/21/2008

net sales of products from Organon, the OBS human health business acquired in 2007.

Sales of REMICADE increased 32 percent to $564 million in the third quarter of 2008 benefiting from continued market growth, expanded penetration and the favorable impact of foreign exchange. REMICADE is a treatment for inflammatory diseases that Schering-Plough markets in countries outside the United States (except in Japan and certain other Asian markets) for rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, pediatric Crohn's disease and ulcerative colitis.

Sales of TEMODAR, a treatment for certain types of brain tumors, grew 27 percent to $273 million, with higher sales in all geographic regions.

Global sales of NASONEX, an inhaled nasal corticosteroid for allergies, rose 6 percent to $258 million versus the 2007 period, due to increased sales in international markets, partially offset by a decline in U.S. sales.

Sales of PEGINTRON for hepatitis C increased 6 percent to $235 million in the 2008 third quarter, primarily due to favorable foreign exchange.

In the women's health franchise, sales for FOLLISTIM/PUREGON, a fertility treatment, for the third quarter of 2008 were $142 million. Sales of NUVARING, a contraceptive product, in the 2008 third quarter were $118 million. These women's health products were obtained as part of the OBS acquisition.

Global sales of CLARINEX, a nonsedating antihistamine, in the third quarter of 2008 were $176 million, an increase of 3 percent as compared to the third quarter of 2007.

International sales of prescription CLARITIN were $87 million in the third quarter of 2008, a 5 percent increase compared to sales of $83 million in the third quarter of 2007 due primarily to foreign exchange.

Animal Health sales totaled $759 million in the 2008 third quarter. Included in the third quarter of 2008 were net sales of $503 m
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine news :

1. Schering-Plough Announces Transition of Animal Health Leadership
2. Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
3. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
4. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
5. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
6. Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
7. Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference
8. Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain
9. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
10. Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... A medical malpractice case which was filed ... by Lori Mandel, an office manager in her 50’s, ... Ms. Mandel sought the medical expertise of an ... that affected the quality of her life and her ... that her doctor rendered conservative treatment for 2 years, ...
(Date:5/23/2013)... can cause rapidly progressing, life threatening meningitis and meningococcal ... have not known how it attaches to the human ... attaches to the airway to colonise", People can be ... while some people progress to invasive disease. To ... how the bacterium colonises the airway. Now that the ...
(Date:5/23/2013)... , , WEDNESDAY, May 22 (HealthDay News) -- The success of ... born with a serious airway malformation sheds light on new ... A report in the May 23 New England Journal ... At first, the baby born five weeks early seemed ... eating when he was 6 weeks old. Just two weeks ...
(Date:5/23/2013)... DRE, Inc. is now offering the DRE ... upgrade older model DRE or BFW halogen headlights to ... , DRE and BFW customers can easily and affordably ... to LED with DRE’s American-made Xavier-C3 LED headlight conversion ... a bright, clean and even field of illumination with ...
(Date:5/23/2013)... May 23, 2013 In Florida, residents have ... This doesn’t mean, however, that Florida’s good luck will continue, ... . This year, he encourages residents, it is important to ... 2013, forecasters are predicting there to be a 50-percent chance ... . With hurricane season lasting from June 1 to November ...
Breaking Medicine News(10 mins):Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 2Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 3Health News:New discovery in fight against deadly meningococcal disease 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 3Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 2Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 3Health News:As Hurricane Season Nears, Skylake Insurance Encourages Florida Residents To Prepare Early For Safety 2
... There,s little benefit to parents or baby in learning before ... new study suggests. Researchers led by Dr. James Robbins, ... 235 mothers of children aged 2 to 7 years with ... condition was identified before birth (prenatally) in 46 percent of ...
... , FRIDAY, Nov. 26 (HealthDay News) -- Most American ... the topic is far less likely to arise in homes without ... half of American households have a gun, and nearly 30 children ... owned by the child,s family or friends, according to researchers at ...
... HealthDay Reporter , WEDNESDAY, Nov. 24 (HealthDay News) ... and want to keep the weight off, a new Danish ... refined carbohydrates. Based on the findings, the researchers advise ... whole-grain breads. The glycemic index (GI) is a measure of ...
... devastating cholera outbreaks in refugee camps in earthquake-wracked Haiti, ... George Washington University, and the International Vaccine Institute (IVI) ... stockpile of cholera vaccines for future humanitarian use. ... maintaining a stockpile of several million doses of cholera ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Nov. 24 ... blood cancers with bone marrow and blood stem cell transplants ... and death, a new study shows. Between the early ... the overall risk of death in an analysis of more ...
... year has brought to light both the promise and ... the most deadly form of skin cancer. Early clinical ... cancer-causing gene revealed impressive results in patients whose cancers ... short-lived, as the tumors invariably returned a few months ...
Cached Medicine News:Health News: Gun-Safety Talk a Safe Bet for All Families, Experts Say 2Health News:More Protein, Fewer Refined Carbs May Keep Weight Off 2Health News:More Protein, Fewer Refined Carbs May Keep Weight Off 3Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 2Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 3Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 4Health News:Study Finds Big Strides Made in Treating Leukemia, Lymphoma in Past Decade 2Health News:Study Finds Big Strides Made in Treating Leukemia, Lymphoma in Past Decade 3Health News:Study Finds Big Strides Made in Treating Leukemia, Lymphoma in Past Decade 4Health News:Researchers shine light on how some melanoma tumors evade drug treatment 2Health News:Researchers shine light on how some melanoma tumors evade drug treatment 3
(Date:5/23/2013)... 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... David A. Ramsay as ... Vice President, Corporate Development at Halozyme. ... his established financial management experience and his recent ... our commercial group for the last four years, ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013  MedVantx, ... to consumer pharmaceutical distribution channel announced today the Company ... platform to manage $1.5B in pharmaceutical products and the ... quality akin to cGMP facilities in its specialty home ... . The Company provides leading pharmaceutical manufacturers, physicians, health ...
(Date:5/23/2013)... , May 23, 2013   BioLife Solutions ... of proprietary clinical grade hypothermic storage and ... and contract aseptic media manufacturer , today announced ... & Regenerative Medicine Congress 2013 this week in ... http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO ) Dr. Aby J. Mathew, BioLife,s ...
Breaking Medicine Technology:Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3
... , RALEIGH, N.C., Dec. 9 ... Head of Infectious Diseases Carl Kraus, M.D., Vice President ... with John Powers, M.D., Assistant Professor of Medicine ... considerations in anti-infective drug development. , Understanding the current ...
... SAN DIEGO, Dec. 9 Sangart, Inc., a global ... to enhance the perfusion and oxygenation of ischemic (oxygen ... initiation of a dose-finding study designed to evaluate the ... care in severely injured trauma patients with lactic acidosis ...
Cached Medicine Technology:PRA International Hosts an Infectious Diseases Audio Conference 2PRA International Hosts an Infectious Diseases Audio Conference 3Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce large devices for vascular intervention....
Medicine Products: